OpenAI researcher Miles Wang is planning to launch an AI drug discovery startup valued at $2 billion. The startup aims to leverage AI to accelerate drug development processes. Lightspeed is reportedly in talks to lead the funding round.
Source preview
Server-side extracted preview paragraphs from the original source.
The funding discussions point to investor interest in applying AI to make breakthroughs in life sciences.
Miles Wang, an OpenAI researcher whose work includes using AI to accelerate scientific and biological discovery, is leaving the ChatGPT maker to launch a new startup focused on developing AI models for drug discovery, according to four people with knowledge...